Steven A. Svoboda

Steven A. Svoboda

Auto-generated profile, based on publicly available information

Steven A. Svoboda

Virginia Tech Carilion School of Medicine Roanoke Virginia USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2021 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
SSSteven A. Svoboda
Steven A. Svoboda
SHSimo Huang
Simo Huang
XLXinyang Liu
Xinyang Liu
SHSylvia Hsu
Sylvia Hsu
KMKiran Motaparthi
Kiran Motaparthi

18 May 2020 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
SSSteven A. Svoboda
Steven A. Svoboda
RGRima I. Ghamrawi
Rima I. Ghamrawi
DODorellie A. Owusu
Dorellie A. Owusu
Steven R. FeldmanSteven R. Feldman
Steven R. Feldman

1 January 2021 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
PDF file
SSSteven A Svoboda
Steven A Svoboda
PRPatrick S Rush
Patrick S Rush
KSKevin G Sharghi
Kevin G Sharghi
PRPeter L Rady
Peter L Rady
STStephen K Tyring
Stephen K Tyring
JEJoshua D Eikenberg
Joshua D Eikenberg
Ustekinumab is a biologic agent with Food and Drug Administration approval for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. It functions to inhibit the p40 subunit common to both interleukin-12 and interleukin-23. These pro-inflammatory cytokines are implicated in autoinflammatory and autoimmune disorders, but they also play an important role in cell-mediated immunity against viral, bacterial, and fungal pathogens. Therefore, antagonism of interleukin-12 and interleukin-23 by ustekinumab may increase the risk of human papillomavirus infection or reactivation which can lead to the development of verrucae. To the best of our knowledge, there is only one published report of disseminated verrucosis secondary to ustekinumab treatment for psoriasis. Here, we present the first case report of ustekinumab-induced disseminated verrucosis occurring in the setting of treatment for Crohn’s disease.

11 November 2020 in Case Reports in Pediatrics
Verified
Journal Article
Open access
PDF file
SSSteven A. Svoboda
Steven A. Svoboda
JEJoshua D. Eikenberg
Joshua D. Eikenberg
Nocardia is an aerobic, Gram-positive, partially acid-fast bacterium that often manifests as pulmonary infection since the primary route of entry is via the respiratory tract. As an opportunistic organism, Nocardia primarily affects immunocompromised individuals. Infection with Nocardia is uncommon. Primary cutaneous nocardiosis which is caused by percutaneous inoculation is even more rare. Here, we report a case of primary cutaneous nocardiosis in an adolescent with Crohn disease receiving treatment with adalimumab and azathioprine. Early identification and treatment are important to prevent disease progression and to avoid severe complications. Diagnosis is made principally by culture. Given that culture results may take up to two weeks to return, primary cutaneous nocardiosis should be maintained in the differential for any superficial cutaneous infection that arises in individuals undergoing treatment with immunosuppressive agents.